GeneDx Holdings (WGS) Receivables - Other (2020 - 2023)

GeneDx Holdings (WGS) has 4 years of Receivables - Other data on file, last reported at $2.9 million in Q2 2023.

• Receivables - Other for Q2 2023 came in at $2.9 million, down 33.53% year-over-year; the trailing twelve-month figure through Jun 2023 was $2.9 million (down 33.53% YoY), and the FY2022 annual result was $1.5 million, up 2677.78% from the prior year.
• Receivables - Other was little changed at $2.9 million in Q2 2023 per WGS's latest filing, from $2.9 million in the prior quarter.
• Over five years, Receivables - Other peaked at $4.4 million in Q2 2022 and troughed at $54000.0 in Q4 2021.
• A 4-year average of $1.9 million and a median of $1.5 million in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2021 and 2022: Receivables - Other sank 81.31% in 2021, then soared 2677.78% in 2022.
• A 4-year view of Receivables - Other shows it stood at $289000.0 in 2020, then slumped by 81.31% to $54000.0 in 2021, then soared by 2677.78% to $1.5 million in 2022, then surged by 93.33% to $2.9 million in 2023.
• Business Quant data shows WGS's Receivables - Other at $2.9 million in Q2 2023, $2.9 million in Q1 2023, and $1.5 million in Q4 2022.